Navigation Links
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Date:10/24/2007

COLLEGEVILLE, Pa., Oct. 24 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's supplemental New Drug Application (sNDA) for its first-in-class antibiotic Tygacil(R) (tigecycline) for the treatment of patients with community-acquired pneumonia (CAP). The FDA now will complete its review of the application. The FDA may approve or disapprove the application, request additional data or take other administrative actions.

"CAP is a serious respiratory disease that affects millions of Americans," says Gary L. Stiles, M.D., Executive Vice President, Chief Medical Officer, Wyeth Pharmaceuticals. "The acceptance of this sNDA is an important event as it brings Wyeth closer to providing physicians with a new option for the treatment of CAP."

The sNDA submission included integrated data from two investigational clinical studies that included 846 patients. Study data showed that Tygacil cured 89.7 percent of patients hospitalized with CAP, and levofloxacin - an existing treatment option for CAP - cured 86.3 percent of studied patients. The most common adverse events for Tygacil were nausea (24.3 percent), vomiting (16.0 percent) and abdominal pain (5.7 percent). The discontinuation rates due to adverse events for Tygacil and levofloxacin were similar (6.1 percent and 8.3 percent, respectively).

"As antibiotic resistance continues to be a concern for many strains of the most common bacteria causing CAP, there is a growing need for new options," says Thomas File, M.D., Chief of Infectious Disease Services for Summa Health System in Akron, Ohio.

About Community-Acquired Pneumonia'/>"/>

SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. American Society of Clinical Oncology (ASCO) Accepts New Data on AVR118 for Publication in 2007 Abstract Book
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. New Quality Control Systems for Every Laboratory Application
4. Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented
5. Antares Pharma Announces Positive Results from Application Site Study for Anturol
6. Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR
7. Point of Care Strep Tests Speed Treatment, Lower Costs
8. Rapid HIV Testing Increases Possibility of Treatment
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  Pete Rose, baseball,s all-time hits leader, is ... pain reliever Myoflex, Ducere Pharma has announced. "Pete,s ... excited to have him on board with Myoflex," said Ducere ... a legendary player who is known across all generations. The ...
(Date:1/23/2015)... MERIDIAN, Idaho , Jan. 23, 2015  Now available ... Patent No. 7,849,611) support that prevents ankle sprains by ... a brace, it fits securely around the outside of ... ankle mobility & comfort while still offering protection against ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Cymetrix, a leader in providing healthcare organizations ... an alliance with Siemens Healthcare for financial system ... Cymetrix will assist in the transition of select ... to Siemens Soarian®. Cymetrix,s system conversion solution preserves ...
... HORSHAM, Pa., Dec. 7, 2010 Topaz Pharmaceuticals Inc., ... completion of two Phase 3 clinical trials that studied ... treatment for head lice. These trials were conducted according ... Food and Drug Administration (FDA). "Parents and ...
Cached Medicine Technology:Cymetrix Forms Alliance With Siemens Healthcare for System Conversion Support 2Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream 2Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream 3
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable ... from 3 p.m. to 4 p.m. on Feb. 13. , The ... serves adults with physical disabilities between the ages of 22 and ... games and sweetheart-themed karaoke. , For more information about the event ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... 2015 VogueQueen is a seasoned and trusted ... many designers are thrilled to have it lead the wedding ... new collection of prom dresses for the global market. , ... strategic vision and he focuses on continuing the goal of ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... CAMBRIDGE, Mass., Oct. 28 Biopure Corporation,(Nasdaq: ... a notice from the,Medicines Control Council (MCC) of ... of Hemopure [hemoglobin glutamer-250,(bovine)], Biopure,s oxygen therapeutic for ... intends to appeal the decision promptly and,expects to ...
... Periodontal disease rises as the joint ailment worsens, research ... arthritis (RA) may increase the risk of gum disease, ... a link between RA and periodontal disease, a condition ... teeth from the gums, loss of bony support, and ...
... NEWPORT BEACH, Calif., Oct. 28 Nationwide,Health Properties, Inc. ... of,Directors declared a $0.44 per share dividend on our ... to shareholders of record on November 14, 2008., ... per share,dividend on our Series B cumulative convertible preferred ...
... Oct. 28 IRIDEX,Corporation (Nasdaq: IRIX ) today ... results after the market closes on Tuesday, November,4, 2008. ... a,conference call with the investment community at 5:00 p.m. ... results of the quarter and other,business developments., Interested ...
... (TSX: RBM, OTCBB: RPBIF) (the "Company") today announced ... financing announced on October,14, 2008 and amended on ... The closing involved a brokered and non-brokered private ... for each unit. Each unit consisted,of one common ...
... 26, 2008) A single administration of a novel, nasally ... were more than 20 times higher than those generated ... to a study by NanoBio Corporation. The new vaccine ... this effect. , Results of the study are being ...
Cached Medicine News:Health News:Agency Takes Adverse Decision to Biopure's Product Registration in South Africa 2Health News:Agency Takes Adverse Decision to Biopure's Product Registration in South Africa 3Health News:Rheumatoid Arthritis May Harm Gums 2Health News:NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 2Health News:NHP Declares Quarterly Cash Dividends on Common Stock and Series B Preferred Stock 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 2Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 3Health News:Response Biomedical Completes Initial Closing of an expected $5.0 Million Financing 4Health News:New intranasal influenza vaccine triggers robust immunity with significantly less antigen 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: